AM6527 / MAKScientific, Tetra Bio-Pharma - LARVOL DELTA

Effects of the neutral CB1 receptor antagonist AM6527 on spontaneous, consummatory, and motivated behavior in mice. (PubMed, Psychopharmacology (Berl)) - "Our findings suggest that neutral CB1R antagonism suppresses consummatory and motivated behaviors via potentially dopamine-dependent and -independent mechanisms. By leveraging sub-second behavioral analysis with MoSeq, we further reveal distinct changes in spontaneous behavior, underscoring the relevance of CB-based treatments for maladaptive appetitive and motivational states in both psychiatric and metabolic disorder."

Journal • Preclinical • Metabolic Disorders • Psychiatry

A neutral CB1R antagonist, AM6527, alters spontaneous behavior and suppresses consummatory and motivational responses (Neuroscience 2025) - "Ongoing work is focused on mapping responsive brain regions by assessing c-Fos expression through immunohistochemistry to better understand whether AM6527 engages distinct or overlapping neural circuits during operant and home-cage behaviors. Overall, these results provide new insight into how CB1R signaling shapes motivational output, offering a framework for developing CB-based interventions that selectively modulate appetitive drive."

CNS Disorders • FOS

AM6527, a neutral CB1 receptor antagonist, suppresses opioid taking and seeking, as well as cocaine seeking in rodents without aversive effects. (PubMed, Neuropsychopharmacology) - "Together, these findings suggest that AM6527 effectively reduces drug-taking and seeking behaviors without rimonabant-like adverse effects. Thus, AM6527 warrants further investigation as a potential pharmacotherapy for opioid and cocaine use disorders."

Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Depression • Psychiatry

The neutral CB1 antagonist AM6527 reduces ethanol seeking, binge-like consumption, reinforcing, and withdrawal effects in male and female mice. (PubMed, Psychopharmacology (Berl)) - "Current findings support previous studies with CB1R neutral antagonist in reducing voluntary ethanol intake and seeking behavior. Based on results shown in this work, AM6527 can be developed as a first in class CB1R neutral antagonist to treat AUD in both males and females."

Journal • Preclinical • Addiction (Opioid and Alcohol) • CNS Disorders • Epilepsy • Mental Retardation • Psychiatry